Cost of schizophrenia to UK society: An incidence-based cost-of-illness model for the first 5 years following diagnosis

PharmacoEconomics

Volumn 15, Issue 6, 1999, Pages 597-610

  Guest, Julian F ^a   Cookson, Ron F ^b  

^a CATALYST Health Economics Consultants   (United Kingdom)

^b Janssen Cilag Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE COURSE; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; MODEL; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIMULATION; UNITED KINGDOM;

COST OF ILLNESS; COSTS AND COST ANALYSIS; GREAT BRITAIN; HUMANS; MODELS, ECONOMIC; SCHIZOPHRENIA;

EID: 0033064214     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915060-00007     Document Type: Article

References (50)

1. 1. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia: implications for the following institutional era in the US. Pharmacoeconomics 1995; 8: 199-222
2. 2. Hyde TM, Weinberger DR. The brain in schizophrenia. Semin Neurol 1990; 10: 276-86
3. 3. Wing JK. Mental illness. In: Stevens A, Raftery J, editors. Epidemiologically based needs assessment. London: HMSO, 1994
4. 4. Goldacre M, Shiwach R, Yeates D. Estimating incidence and prevalence of treated psychiatric disorders from routine statistics: the example of schizophrenia. J Epidemiol Commun Health 1994; 48 (3): 318-22
5. 5. Castle D, Wessely S, Der G, et al. The incidence of operationally defined schizophrenia in Camberwell, 1965-84. Br J Psychiatry 1991; 159: 790-4
6. 6. Harrison G, Cooper JE, Gancarezyk R. Changes in the administrative incidence of schizophrenia. Br J Psychiatry 1991; 159: 811-6
7. 7. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull 1990; 14: 522-5
8. 8. Crow TJ. Schizophrenia: diagnostic boundaries, epidemiology and brain changes. Clinician 1993; 11: 2-17
9. 9. RL Gregory. The Oxford companion to the mind 1987. Oxford: Oxford University Press, 1987
10. 10. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; 165 Suppl. 25: 18-21
11. 11. Langley-Hawthorne C. Modelling the lifetime costs of treating schizophrenia in Australia. Clin Ther 1997; 19 (6): 1470-95
12. 12. The Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study VIII. Five year follow-up: clinical and psychosocial findings. Br J Psychiatry 1992; 161: 496-500
13. 13. Geddes J, Mercer G, Frith CD, et al. Prediction of outcome following a first episode of schizophrenia: a follow-up study of Northwick Park first episode study subjects. Br J Psychiatry 1994; 165: 664-8
14. 14. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993; 54 (3 Suppl.): 13-7
15. 15. Johnstone EC, Geddes J. How high is the relapse rate in schizophrenia? Acta Psychiatr Scand 1994; 89 Suppl. 382: 6-10
16. 16. Shepherd M, Watt D, Falloon I, et al. The natural history of schizophrenia: a five year follow-up of outcome and prediction in a representative sample of schizophrenics. Psychol Med Monogr Suppl 1989; 15: 1-46
17. 17. Brenner HD, Dencker SJ, Goldstein MJ, et al. Defining treatmem refractoriness in schizophrenia. Schizophr Bull 1990; 16: 551-62
18. 18. Schruben LW. Graphical simulation modeling and analysis. Danvers (MA); Boyd & Fraser, 1995
19. 19. Wieselrgen IM, Lindstrom LH. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenia patients: relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment. Acta Psychiatr Scand 1996; 93: 9-19
20. 20. Baldwin JA. Schizophrenia and physical disease. Psychol Med 1979; 9: 611-8
21. 21. Allebeck P. Schizophrenia: a life-shortening disease. Schizophr Bull 1989; 151 (1): 81-9
22. 22. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993; 163: 183-9
23. 23. Roy A. Suicide in chronic schizophrenia. Br J Psychiatry 1982; 141: 171-7
24. 24. Fenton WS, McGlashan TH, Victor BJ, et al. Symptoms, subtype and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 1997; 154: 199-204
25. 25. Netten A, Dennett J. Unit costs of health and social care 1996. Canterbury: Personal Social Service Research Unit, University of Kent at Canterbury, 1996
26. 26. Knapp M, Kavanagh S. Economic outcomes and costs in the treatment of schizophrenia. ClinTher 1997; 19 (1): 128-38
27. 27. Lelliott P, Audini B, Knapp MRJ, et al. Mental health residential care: classification of facilities and description of services. Br J Psychiatry 1996: 169; 139-47
28. 28. Monthly index of medical specialities. London: Haymarket Publications Ltd., 1997
29. 29. Department of Health. Drug tariff. London: HMSO, 1997
30. 30. Office of National Statistics. Labour market trends. London: HMSO, 1997
31. 31. The Treasury. Annex G: the cost of capital discount rates and required rates of return. In: Appraisal and evaluation in central government. London: HMSO, 1997: 77
32. 32. Kavanagh SM, Opit LJ, Knapp M, et al. Schizophrenia: shifting the balance of care. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 206-12
33. 33. Johnstone EC, Frith JD, Leary J, et al. Background, method and general description of the sample. Br J Psychiatry 1991; 159 Suppl. 13: 43-6
34. 34. Knapp M. Costs of schizophrenia. Br J Psychiatry 1997; 171: 509-18
35. 35. Tollefson GD, Beasely CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-65
36. 36. Gerlach J, Peacock L. Motor and mental side effects of clozapine. J Clin Psychiatry 1994; 55 (9 Suppl. B): 107-9
37. 37. Chakos MH, Mayerhoff DI, Loebel AD, et al. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992; 28: 81-6
38. 38. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13 (1): 25-40
39. 39. Kopala LC, Good, KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low dose risperidone. J Clin Psychopharmacol 1997; 17: 308-13
40. 40. Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of randomised controlled trials. J Psychopharmacol 1997; 11 (1): 65-71
41. 41. Honigfeld G, Pattin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Commununity Psychiatry 1990; 41 (8): 882-5
42. 42. Frangou S, Murray RM. Schizophrenia. London: Martin Dunitz Ltd., 1996: 64-5
43. 43. Leary J, Johnstonc EC, Owens DGC. Disabilities and circumstances of schizophrenic patients: a follow up study. II: social outcome. Br J Psychiatry 1991; 159 Suppl. 13: 13-20
44. 44. Foster K, Meltzer H, Gill B, et al. OPCS surveys of psychiatry morbidity report 8: adults with a psychotic disorder living in the community. London: HMSO, 1996
45. 45. McGuire TG. Measuring the economic costs of schizophrenia. Schizophr Bull 1991; 17: 375-81
46. 46. National Health Service Executive (NHSE). Burden of disease. Leeds. NHSE, 1996
47. 47. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-29
48. 48. Cookson RF, Huybrechts KF. Risperidone: an assessment of its economic benefits in the treatment of schizophrenia. J Med Econ 1998; 1: 103-34
49. 49. Guest JF, Hart WM, Cookson RF, et at. Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br J Med Econ 1996; 10: 59-67
50. 50. Johnson S, Ramsey R, Thornicroft G. London's mental health. London: King's Fund, 1997